Journal
JOURNAL OF PEDIATRICS
Volume 154, Issue 5, Pages 688-693Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2008.11.030
Keywords
-
Categories
Funding
- Department of Education and Culture of the Golbiemo de Navarra
Ask authors/readers for more resources
Objective To determine the influence of the genotype and the level of expression of different enzymes involved in folate metabolism on the response to and toxicity of high-dose methotrexate treatment in pediatric osteosarcomas. Study design DHFR and Reduced folate carrier 1 (RFC1) semiquantitative expression was analyzed in 34 primary and metastatic osteosarcoma tissues by real-time polymerase chain reaction. The following polymorphisms were also analyzed in peripheral blood from 96 children with osteosarcoma and 110 control subjects: C677T, A1298C (MTHFR), G80A (RFC1), A2756G (MTR), C1420T (SHMT), the 28bp-repeat polymorphism, and 1494del6 of the TYMS gene. Treatment toxicity was scored after each cycle according to criteria from the World Health Organization. Results DHFR and RFC1 expression was lower in initial osteosarcoma biopsy specimens than in metastases (P =.024 and P =.041, respectively). RFC1 expression was moderately decreased in samples with poor histologic response to preoperative treatment (P = .053). Patients with osteosarcoma with G3/G4 hematologic toxicity were more frequently TT than CT/CC for C677T/MTHFR (P =.023) and GG for A2756G/MTR (P =.048 and P =.057 for gastrointestinal and hematologic toxicity, respectively). Conclusions The role of C677T/MTHFR and A2756G/MTR on chemotherapy-induced toxicity should be further investigated in pediatric osteosarcomas receiving high-dose methotrexate. Altered expression of DHFR and RFC1 is a feasible mechanism by which osteosarcoma cells become resistant to methotrexate. (J Pediatr 2009;154:688-9.3)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available